Plasma biomarkers differentiate Parkinson's disease from atypical parkinsonism syndromes

Chin Hsien Lin, Shieh Yueh Yang, Herng Er Horng, Che Chuan Yang, Jen Jie Chieh, Hsin Hsien Chen, Bing Hsien Liu, Ming Jang Chiu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples (n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism. We measured plasma levels of α-synuclein, total tau, p-Tau181, and amyloid beta 42 (Aβ42) by immunomagnetic reduction-based immunoassay. Results: Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (p < 0.01). Total tau and p-Tau181 were significantly increased in all disease groups compared to controls, especially in patients with FTD (p < 0.01). A multivariate and receiver operating characteristic curve analysis revealed that a cut-offvalue for Aβ42 multiplied by p-Tau181 for discriminating patients with FTD from patients with PD and APS was 92.66 (pg/ml)2, with an area under the curve (AUC) of 0.932. An α-synuclein cut-offof 0.1977 pg/ml could separate FTD-P from FTD without parkinsonism (AUC 0.947). In patients with predominant parkinsonism, an α-synuclein cut-offof 1.388 pg/ml differentiated patients with PD from those with APS (AUC 0.87). Conclusion: Our results suggest that integrated plasma biomarkers improve the differential diagnosis of PD from APS (PSP, CBD, DLB, and FTD-P).

Original languageEnglish
Article number123
JournalFrontiers in Aging Neuroscience
Volume10
Issue numberAPR
DOIs
Publication statusPublished - 2018 Apr 27

Fingerprint

Parkinsonian Disorders
Frontotemporal Dementia
Biomarkers
Synucleins
Parkinson Disease
Area Under Curve
Progressive Supranuclear Palsy
Lewy Body Disease
Amyloid
Parkinson Disease, Familial, Type 1
Multiple System Atrophy
Immunoassay
ROC Curve
Dementia
Differential Diagnosis

Keywords

  • A-synuclein
  • Amyloid beta 42
  • Atypical parkinsonism syndrome
  • P-Tau181
  • Parkinson's disease
  • Tau

ASJC Scopus subject areas

  • Ageing
  • Cognitive Neuroscience

Cite this

Plasma biomarkers differentiate Parkinson's disease from atypical parkinsonism syndromes. / Lin, Chin Hsien; Yang, Shieh Yueh; Horng, Herng Er; Yang, Che Chuan; Chieh, Jen Jie; Chen, Hsin Hsien; Liu, Bing Hsien; Chiu, Ming Jang.

In: Frontiers in Aging Neuroscience, Vol. 10, No. APR, 123, 27.04.2018.

Research output: Contribution to journalArticle

Lin, Chin Hsien ; Yang, Shieh Yueh ; Horng, Herng Er ; Yang, Che Chuan ; Chieh, Jen Jie ; Chen, Hsin Hsien ; Liu, Bing Hsien ; Chiu, Ming Jang. / Plasma biomarkers differentiate Parkinson's disease from atypical parkinsonism syndromes. In: Frontiers in Aging Neuroscience. 2018 ; Vol. 10, No. APR.
@article{7813c3e53abb45119572435392be36c2,
title = "Plasma biomarkers differentiate Parkinson's disease from atypical parkinsonism syndromes",
abstract = "Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples (n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism. We measured plasma levels of α-synuclein, total tau, p-Tau181, and amyloid beta 42 (Aβ42) by immunomagnetic reduction-based immunoassay. Results: Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (p < 0.01). Total tau and p-Tau181 were significantly increased in all disease groups compared to controls, especially in patients with FTD (p < 0.01). A multivariate and receiver operating characteristic curve analysis revealed that a cut-offvalue for Aβ42 multiplied by p-Tau181 for discriminating patients with FTD from patients with PD and APS was 92.66 (pg/ml)2, with an area under the curve (AUC) of 0.932. An α-synuclein cut-offof 0.1977 pg/ml could separate FTD-P from FTD without parkinsonism (AUC 0.947). In patients with predominant parkinsonism, an α-synuclein cut-offof 1.388 pg/ml differentiated patients with PD from those with APS (AUC 0.87). Conclusion: Our results suggest that integrated plasma biomarkers improve the differential diagnosis of PD from APS (PSP, CBD, DLB, and FTD-P).",
keywords = "A-synuclein, Amyloid beta 42, Atypical parkinsonism syndrome, P-Tau181, Parkinson's disease, Tau",
author = "Lin, {Chin Hsien} and Yang, {Shieh Yueh} and Horng, {Herng Er} and Yang, {Che Chuan} and Chieh, {Jen Jie} and Chen, {Hsin Hsien} and Liu, {Bing Hsien} and Chiu, {Ming Jang}",
year = "2018",
month = "4",
day = "27",
doi = "10.3389/fnagi.2018.00123",
language = "English",
volume = "10",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "APR",

}

TY - JOUR

T1 - Plasma biomarkers differentiate Parkinson's disease from atypical parkinsonism syndromes

AU - Lin, Chin Hsien

AU - Yang, Shieh Yueh

AU - Horng, Herng Er

AU - Yang, Che Chuan

AU - Chieh, Jen Jie

AU - Chen, Hsin Hsien

AU - Liu, Bing Hsien

AU - Chiu, Ming Jang

PY - 2018/4/27

Y1 - 2018/4/27

N2 - Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples (n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism. We measured plasma levels of α-synuclein, total tau, p-Tau181, and amyloid beta 42 (Aβ42) by immunomagnetic reduction-based immunoassay. Results: Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (p < 0.01). Total tau and p-Tau181 were significantly increased in all disease groups compared to controls, especially in patients with FTD (p < 0.01). A multivariate and receiver operating characteristic curve analysis revealed that a cut-offvalue for Aβ42 multiplied by p-Tau181 for discriminating patients with FTD from patients with PD and APS was 92.66 (pg/ml)2, with an area under the curve (AUC) of 0.932. An α-synuclein cut-offof 0.1977 pg/ml could separate FTD-P from FTD without parkinsonism (AUC 0.947). In patients with predominant parkinsonism, an α-synuclein cut-offof 1.388 pg/ml differentiated patients with PD from those with APS (AUC 0.87). Conclusion: Our results suggest that integrated plasma biomarkers improve the differential diagnosis of PD from APS (PSP, CBD, DLB, and FTD-P).

AB - Objective: Parkinson's disease (PD) has significant clinical overlaps with atypical parkinsonism syndromes (APS), which have a poorer treatment response and a more aggressive course than PD. We aimed to identify plasma biomarkers to differentiate PD from APS. Methods: Plasma samples (n = 204) were obtained from healthy controls and from patients with PD, dementia with Lewy bodies (DLB), multiple system atrophy, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or frontotemporal dementia (FTD) with parkinsonism (FTD-P) or without parkinsonism. We measured plasma levels of α-synuclein, total tau, p-Tau181, and amyloid beta 42 (Aβ42) by immunomagnetic reduction-based immunoassay. Results: Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (p < 0.01). Total tau and p-Tau181 were significantly increased in all disease groups compared to controls, especially in patients with FTD (p < 0.01). A multivariate and receiver operating characteristic curve analysis revealed that a cut-offvalue for Aβ42 multiplied by p-Tau181 for discriminating patients with FTD from patients with PD and APS was 92.66 (pg/ml)2, with an area under the curve (AUC) of 0.932. An α-synuclein cut-offof 0.1977 pg/ml could separate FTD-P from FTD without parkinsonism (AUC 0.947). In patients with predominant parkinsonism, an α-synuclein cut-offof 1.388 pg/ml differentiated patients with PD from those with APS (AUC 0.87). Conclusion: Our results suggest that integrated plasma biomarkers improve the differential diagnosis of PD from APS (PSP, CBD, DLB, and FTD-P).

KW - A-synuclein

KW - Amyloid beta 42

KW - Atypical parkinsonism syndrome

KW - P-Tau181

KW - Parkinson's disease

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85046337297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046337297&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2018.00123

DO - 10.3389/fnagi.2018.00123

M3 - Article

AN - SCOPUS:85046337297

VL - 10

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - APR

M1 - 123

ER -